Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
influenza monovalent whole virus (H5N1) vaccine (GSK)
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This is an inactivated whole-virus monovalent vaccine developed by GlaxoSmithKline (GSK) to protect against the H5N1 strain of Influenza A, a highly pathogenic avian influenza virus with pandemic potential. Unlike split-virus or subunit vaccines, this whole-virus formulation contains the entire inactivated viral particle, which preserves all structural proteins and can potentially enhance immunogenicity. The vaccine was evaluated in clinical trials (such as NCT00309634) in both adjuvanted (using aluminum hydroxide) and non-adjuvanted forms to determine the optimal dose and vaccination schedule for pandemic preparedness in healthy adults.
- Other names
- H5N1 whole virus vaccineH-5N1 whole virus vaccineH 5N1 whole virus vaccineGSK H5N1 whole virus vaccineinfluenza monovalent whole virus (h5n1)
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on influenza monovalent whole virus (H5N1) vaccine (GSK).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on influenza monovalent whole virus (H5N1) vaccine (GSK).